Evidence map›Paper›PMID 33432763›Full record

ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2021

The clinical characterization of the patient with primary psychosis aimed at personalization of management.

Mario Maj, Jim van Os, Marc De Hert, Wolfgang Gaebel, Silvana Galderisi, Michael F Green, Sinan Guloksuz, Philip D Harvey, Peter B Jones, Dolores Malaspina and 8 more

Abstract read
In one paragraph

Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. An etiological approach to psychosis: potential benefits for treatment, research and prevention.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mario MajDepartment of Psychiatry, University of Campania "L. Vanvitelli", Naples, Italy.
Jim van OsDepartment of Psychiatry, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, The Netherlands.
Marc De HertUniversity Psychiatric Centre KU Leuven, Kortenberg, Belgium.
Wolfgang GaebelDepartment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University Düsseldorf, LVR-Klinikum Düsseldorf, and WHO Collaborating Center on Quality Assurance and Empowerment in Mental Health, Düsseldorf, Germany.
Silvana GalderisiDepartment of Psychiatry, University of Campania "L. Vanvitelli", Naples, Italy.
Michael F GreenDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
Sinan GuloksuzDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.
Philip D HarveyDivision of Psychology, Department of Psychiatry, University of Miami Miller School of Medicine, Miami, FL, USA.
Peter B JonesDepartment of Psychiatry, University of Cambridge and Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.
Dolores MalaspinaDepartment of Psychiatry and Neuroscience, Ichan Medical School at Mount Sinai, New York, NY, USA.
Patrick McGorryOrygen, Parkville, VIC, Australia.
Jouko MiettunenCentre for Life Course Health Research, University of Oulu, Oulu, Finland.
Robin M MurrayInstitute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Keith H NuechterleinSemel Institute for Neuroscience and Human Behavior, Geffen School of Medicine, and Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA.
Victor PeraltaMental Health Department, Servicio Navarro de Salud, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Graham ThornicroftCentre for Global Mental Health and Centre for Implementation Science, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Ruud van WinkelDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.
Joseph VenturaDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current management of patients with primary psychosis worldwide is often remarkably stereotyped. In almost all cases an antipsychotic medica-tion is prescribed, with second-generation antipsychotics usually preferred to first-generation ones. Cognitive behavioral therapy is rarely used in the vast majority of countries, although there is evidence to support its efficacy. Psychosocial interventions are often provided, especially in chronic cases, but those applied are frequently not validated by research. Evidence-based family interventions and supported employment programs are seldom implemented in ordinary practice. Although the notion that patients with primary psychosis are at increased risk for cardiovascular diseases and diabetes mellitus is widely shared, it is not frequent that appropriate measures be implemented to address this problem. The view that the management of the patient with primary psychosis should be personalized is endorsed by the vast majority of clinicians, but this personalization is lacking or inadequate in most clinical contexts. Although many mental health services would declare themselves "recovery-oriented", it is not common that a focus on empowerment, identity, meaning and resilience is ensured in ordinary practice. The present paper aims to address this situation. It describes systematically the salient domains that should be considered in the characterization of the individual patient with primary psychosis aimed at personalization of management. These include positive and negative symptom dimensions, other psychopathological components, onset and course, neurocognition and social cognition, neurodevelopmental indicators; social functioning, quality of life and unmet needs; clinical staging, antecedent and concomitant psychiatric conditions, physical comorbidities, family history, history of obstetric complications, early and recent environmental exposures, protective factors and resilience, and internalized stigma. For each domain, simple assessment instruments are identified that could be considered for use in clinical practice and included in standardized decision tools. A management of primary psychosis is encouraged which takes into account all the available treatment modalities whose efficacy is supported by research evidence, selects and modulates them in the individual patient on the basis of the clinical characterization, addresses the patient's needs in terms of employment, housing, self-care, social relationships and education, and offers a focus on identity, meaning and resilience.

Indexed as

environmental exposuresfamily historyinternalized stigmanegative dimensionneurocognitionobstetric complicationspersonalization of treatmentphysical comorbiditiespositive dimensionpractical needsPrimary psychosisprotective factorspsychiatric antecedentspsychiatric comorbiditiespsychosocial interventionsrecoveryresilienceschizophreniasocial cognitionsocial functioning

Identifiers

PMID33432763
PMCPMC7801854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.